Clinical Trial Update: A Study of Ivonescimab in First-Line ES-SCLC [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Ivonescimab as first-line treatment in extensive-stage small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Akeso | Conditions: Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Status: RECRUITING